Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11952915 | 0.95 | MAPK1 (0.36) | MAPK1OPRM1OPRL1OPRK1ALDH1A1 | |
| SCHEMBL10060271 | 0.93 | OPRM1 (0.34) | OPRM1OPRL1OPRK1 | |
| SCHEMBL10060268 | 0.84 | MAPK1 (0.36) | MAPK1ALDH1A1MCOLN3 | |
| SCHEMBL10079285 | 0.84 | MAPK1 (0.36) | MAPK1OPRM1OPRL1OPRK1ALDH1A1 | |
| SCHEMBL10060273 | 0.84 | OPRM1 (0.31) | OPRM1OPRL1OPRK1 | |
| SCHEMBL12771389 | 0.78 | PIK3CD (0.38) | OPRM1OPRL1OPRK1 | |
| SCHEMBL12771380 | 0.78 | PIK3CD (0.38) | OPRM1OPRL1OPRK1 | |
| SCHEMBL4737540 | 0.73 | MAPK1 (0.38) | MAPK1OPRM1OPRL1OPRK1ALDH1A1 | |
| SCHEMBL11952911 | 0.71 | — | — | |
| SCHEMBL10060262 | 0.71 | ACE (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-20120195915-A1 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120195915-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | MAPK1 890/4885OPRM1 4489/4885OPRL1 3302/4885 |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | MAPK1 890/4885OPRM1 4489/4885OPRL1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.